The University of Southampton
University of Southampton Institutional Repository

Investigation of potential pro-apoptotic and differentiating therapeutic modalities in breast cancer cells

Investigation of potential pro-apoptotic and differentiating therapeutic modalities in breast cancer cells
Investigation of potential pro-apoptotic and differentiating therapeutic modalities in breast cancer cells

Firstly investigation addressed the ability of the anti-apoptotic protein BAG-1, which potentiates the oestrogen receptor in breast cancer, to also modulate PPARγ (peroxisome proliferator activated receptor γ), a nuclear hormone receptor important for lipid and glucose homeostasis.  PPARγ agonists represent a potential therapeutic approach for breast cancer, inducing cell cycle arrest, apoptosis and differentiation.  Prostaglandin J2 (PGJ2) stimulated PPARγ mediated expression of HSP70, a BAG-1 binding partner, but not BAG-1 isoform expression.  BAG-1 over expression did not alter PGJ2 dependent transcription, or interfere with PGJ2-induced cell cycle arrest or differentiation.  However, BAG-1 did not interfere with induction of cell death by PGJ2. Thus, BAG-1 is unlikely to directly modulate PPAR, but its known over expression in some breast cancers might limit potential clinical efficacy of PPARγ agonists, by suppression of PPARγ-induced cell death pathways.

Secondly, a depsipeptide natural compound, Spiruchostatin A, was characterised with respect to its histone deacetylase (HDAC) activity and ability to induce cell cycle arrest, differentiation and cell death in breast cancer cells.  Differences in potency, cell cycle arrest characteristics and induction of cell death were detected for Spiruchostatin A in breast cancer versus normal cells.  Comparative investigation of the depsipeptide HDAC inhibitors Spiruchostatin A and FK-228 demonstrated class I HDAC selectivity in distinction to hydroxamate pan HDAC class I and II inhibitors.  Class I HDAC selectivity allowed for the retention of anti breast cancer cell histone acetylation pharmacodynamics with implications for in-vivo surrogate markers of downstream biological effects of these compounds.

University of Southampton
Crabb, Simon John
830ac40c-d047-4231-8d36-2ccf06df2adc
Crabb, Simon John
830ac40c-d047-4231-8d36-2ccf06df2adc

Crabb, Simon John (2006) Investigation of potential pro-apoptotic and differentiating therapeutic modalities in breast cancer cells. University of Southampton, Doctoral Thesis.

Record type: Thesis (Doctoral)

Abstract

Firstly investigation addressed the ability of the anti-apoptotic protein BAG-1, which potentiates the oestrogen receptor in breast cancer, to also modulate PPARγ (peroxisome proliferator activated receptor γ), a nuclear hormone receptor important for lipid and glucose homeostasis.  PPARγ agonists represent a potential therapeutic approach for breast cancer, inducing cell cycle arrest, apoptosis and differentiation.  Prostaglandin J2 (PGJ2) stimulated PPARγ mediated expression of HSP70, a BAG-1 binding partner, but not BAG-1 isoform expression.  BAG-1 over expression did not alter PGJ2 dependent transcription, or interfere with PGJ2-induced cell cycle arrest or differentiation.  However, BAG-1 did not interfere with induction of cell death by PGJ2. Thus, BAG-1 is unlikely to directly modulate PPAR, but its known over expression in some breast cancers might limit potential clinical efficacy of PPARγ agonists, by suppression of PPARγ-induced cell death pathways.

Secondly, a depsipeptide natural compound, Spiruchostatin A, was characterised with respect to its histone deacetylase (HDAC) activity and ability to induce cell cycle arrest, differentiation and cell death in breast cancer cells.  Differences in potency, cell cycle arrest characteristics and induction of cell death were detected for Spiruchostatin A in breast cancer versus normal cells.  Comparative investigation of the depsipeptide HDAC inhibitors Spiruchostatin A and FK-228 demonstrated class I HDAC selectivity in distinction to hydroxamate pan HDAC class I and II inhibitors.  Class I HDAC selectivity allowed for the retention of anti breast cancer cell histone acetylation pharmacodynamics with implications for in-vivo surrogate markers of downstream biological effects of these compounds.

Text
1034324.pdf - Version of Record
Available under License University of Southampton Thesis Licence.
Download (2MB)

More information

Published date: 2006

Identifiers

Local EPrints ID: 466080
URI: http://eprints.soton.ac.uk/id/eprint/466080
PURE UUID: a1a79044-fc68-44ca-a1fb-66d2e259d407

Catalogue record

Date deposited: 05 Jul 2022 04:15
Last modified: 16 Mar 2024 20:30

Export record

Contributors

Author: Simon John Crabb

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×